MONTPELLIER, FRANCE & BOSTON, MASS. — Cilcare announced an update to its licensing agreement with Sanofi covering its two lead programs, CIL001 and CIL003. The revised agreement includes improved royalty terms for Cilcare and will make Sanofi a minority shareholder in the company....
No actionable change; this is an early-stage industry investment deal with no approved treatments or clinical guidance resulting from it.
A major pharma player deepening its financial commitment to hearing therapeutics signals growing industry confidence that drug-based treatments for hearing loss may reach the clinic within the coming years.
- 01Sanofi has taken a minority equity stake in Cilcare, expanding their existing partnership.
- 02The revised licensing agreement includes improved royalty terms favouring Cilcare.
- 03The deal covers CIL001 and CIL003, Cilcare's two lead hearing therapeutic candidates.
- 04Neither drug candidate has reported Phase 3 data or regulatory approval.
- 05The announcement reflects a broader trend of large pharma investment in hearing health drug pipelines.
Sanofi has taken a minority equity stake in Cilcare.
press releasesupportedSanofi and Cilcare have revised their licensing agreement with improved royalty terms for Cilcare.
press releasesupportedThe partnership covers Cilcare's two lead hearing therapeutic programs, CIL001 and CIL003.
press releasesupported
